175 related articles for article (PubMed ID: 19748537)
1. Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model.
Zhao H; Kiptoo P; Williams TD; Siahaan TJ; Topp EM
J Control Release; 2010 Jan; 141(2):145-52. PubMed ID: 19748537
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis.
Büyüktimkin B; Wang Q; Kiptoo P; Stewart JM; Berkland C; Siahaan TJ
Mol Pharm; 2012 Apr; 9(4):979-85. PubMed ID: 22375937
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics.
Ridwan R; Kiptoo P; Kobayashi N; Weir S; Hughes M; Williams T; Soegianto R; Siahaan TJ
J Pharmacol Exp Ther; 2010 Mar; 332(3):1136-45. PubMed ID: 20026673
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.
Kobayashi N; Kobayashi H; Gu L; Malefyt T; Siahaan TJ
J Pharmacol Exp Ther; 2007 Aug; 322(2):879-86. PubMed ID: 17522343
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.
Kobayashi N; Kiptoo P; Kobayashi H; Ridwan R; Brocke S; Siahaan TJ
Clin Immunol; 2008 Oct; 129(1):69-79. PubMed ID: 18676182
[TBL] [Abstract][Full Text] [Related]
6. Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.
Badawi AH; Siahaan TJ
J Neuroimmunol; 2013 Oct; 263(1-2):20-7. PubMed ID: 23911075
[TBL] [Abstract][Full Text] [Related]
7. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch.
Huan J; Subramanian S; Jones R; Rich C; Link J; Mooney J; Bourdette DN; Vandenbark AA; Burrows GG; Offner H
J Immunol; 2004 Apr; 172(7):4556-66. PubMed ID: 15034073
[TBL] [Abstract][Full Text] [Related]
8. Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.
Sestak JO; Fakhari A; Badawi AH; Siahaan TJ; Berkland C
AAPS J; 2014 Nov; 16(6):1185-93. PubMed ID: 25193268
[TBL] [Abstract][Full Text] [Related]
9. An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.
Cho JJ; Stewart JM; Drashansky TT; Brusko MA; Zuniga AN; Lorentsen KJ; Keselowsky BG; Avram D
Biomaterials; 2017 Oct; 143():79-92. PubMed ID: 28772190
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Injection of Myelin Oligodendrocyte Glycoprotein-coated PLGA Microparticles Have Tolerogenic Effects in Experimental Autoimmune Encephalomyelitis.
Gholamzad M; Ebtekar M; Shafiee Ardestani M
Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):271-281. PubMed ID: 28732440
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.
Whitham RH; Bourdette DN; Hashim GA; Herndon RM; Ilg RC; Vandenbark AA; Offner H
J Immunol; 1991 Jan; 146(1):101-7. PubMed ID: 1701788
[TBL] [Abstract][Full Text] [Related]
12. Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis.
Wegmann KW; Archie Bouwer HG; Whitham RH; Hinrichs DJ
J Neuroimmunol; 2014 Sep; 274(1-2):46-52. PubMed ID: 24997489
[TBL] [Abstract][Full Text] [Related]
13. Highly loaded, sustained-release microparticles of curcumin for chemoprevention.
Shahani K; Panyam J
J Pharm Sci; 2011 Jul; 100(7):2599-609. PubMed ID: 21547911
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.
Northrup L; Griffin JD; Christopher MA; Antunez LR; Hartwell BL; Pickens CJ; Berkland C
J Control Release; 2017 Nov; 266():156-165. PubMed ID: 28963036
[TBL] [Abstract][Full Text] [Related]
15. Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.
Kiptoo P; Büyüktimkin B; Badawi AH; Stewart J; Ridwan R; Siahaan TJ
Clin Exp Immunol; 2013 Apr; 172(1):23-36. PubMed ID: 23480182
[TBL] [Abstract][Full Text] [Related]
16. Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis.
Kel J; Oldenampsen J; Luca M; Drijfhout JW; Koning F; Nagelkerken L
Am J Pathol; 2007 Jan; 170(1):272-80. PubMed ID: 17200200
[TBL] [Abstract][Full Text] [Related]
17. Sequence 104-117 of myelin proteolipid protein is a cryptic encephalitogenic T cell determinant for SJL/J mice.
Tuohy VK; Thomas DM
J Neuroimmunol; 1995 Feb; 56(2):161-70. PubMed ID: 7532182
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance mediated by recombinant proteolipid protein prevents experimental autoimmune encephalomyelitis.
Elliott EA; Cofiell R; Wilkins JA; Raine CS; Matis LA; Mueller JP
J Neuroimmunol; 1997 Oct; 79(1):1-11. PubMed ID: 9357441
[TBL] [Abstract][Full Text] [Related]
19. Oral Administration of Lactococcus lactis Expressing Synthetic Genes of Myelin Antigens in Decreasing Experimental Autoimmune Encephalomyelitis in Rats.
Kasarello K; Kwiatkowska-Patzer B; Lipkowski AW; Bardowski JK; Szczepankowska AK
Med Sci Monit; 2015 May; 21():1587-97. PubMed ID: 26026273
[TBL] [Abstract][Full Text] [Related]
20. Induction of experimental allergic encephalomyelitis by myelin proteolipid-protein-specific T cell clones and synthetic peptides.
Kuchroo VK; Sobel RA; Yamamura T; Greenfield E; Dorf ME; Lees MB
Pathobiology; 1991; 59(5):305-12. PubMed ID: 1716908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
